دورية أكاديمية
أعرض في EDS

Sunitinib promotes myogenic regeneration and mitigates disease progression in the mdx mouse model of Duchenne muscular dystrophy.

التفاصيل البيبلوغرافية
العنوان: Sunitinib promotes myogenic regeneration and mitigates disease progression in the mdx mouse model of Duchenne muscular dystrophy.
المؤلفون: Fontelonga TM; Department of Pharmacology, University of Nevada, Reno School of Medicine, , Reno, NV, USA., Jordan B; Department of Pharmacology, University of Nevada, Reno School of Medicine, , Reno, NV, USA., Nunes AM; Department of Pharmacology, University of Nevada, Reno School of Medicine, , Reno, NV, USA., Barraza-Flores P; Department of Pharmacology, University of Nevada, Reno School of Medicine, , Reno, NV, USA., Bolden N; Department of Pharmacology, University of Nevada, Reno School of Medicine, , Reno, NV, USA., Wuebbles RD; Department of Pharmacology, University of Nevada, Reno School of Medicine, , Reno, NV, USA., Griner LM; Division of Pre-clinical Innovation, NIH Center for Advancing Translational Sciences, Rockville, MD, USA., Hu X; Division of Pre-clinical Innovation, NIH Center for Advancing Translational Sciences, Rockville, MD, USA., Ferrer M; Division of Pre-clinical Innovation, NIH Center for Advancing Translational Sciences, Rockville, MD, USA., Marugan J; Division of Pre-clinical Innovation, NIH Center for Advancing Translational Sciences, Rockville, MD, USA., Southall N; Division of Pre-clinical Innovation, NIH Center for Advancing Translational Sciences, Rockville, MD, USA., Burkin DJ; Department of Pharmacology, University of Nevada, Reno School of Medicine, , Reno, NV, USA.
المصدر: Human molecular genetics [Hum Mol Genet] 2019 Jul 01; Vol. 28 (13), pp. 2120-2132.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: IRL Press at Oxford University Press Country of Publication: England NLM ID: 9208958 Publication Model: Print Cited Medium: Internet ISSN: 1460-2083 (Electronic) Linking ISSN: 09646906 NLM ISO Abbreviation: Hum Mol Genet Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Oxford, England ; New York : IRL Press at Oxford University Press, c1992-
مواضيع طبية MeSH: Muscle, Skeletal/*drug effects , Muscular Dystrophy, Duchenne/*drug therapy , Myoblasts/*drug effects , Sunitinib/*therapeutic use, Animals ; Cell Line ; Disease Models, Animal ; Disease Progression ; Integrins/metabolism ; Male ; Mice ; Mice, Inbred mdx ; Muscle Development/drug effects ; Muscle, Skeletal/metabolism ; MyoD Protein/metabolism ; Myoblasts/cytology ; Myoblasts/metabolism ; Myogenin/metabolism ; Protein Tyrosine Phosphatase, Non-Receptor Type 6/drug effects ; Protein Tyrosine Phosphatase, Non-Receptor Type 6/metabolism ; Regeneration ; STAT3 Transcription Factor/drug effects ; STAT3 Transcription Factor/metabolism ; Satellite Cells, Skeletal Muscle/drug effects ; Satellite Cells, Skeletal Muscle/metabolism ; Sunitinib/pharmacology
مستخلص: Duchenne muscular dystrophy (DMD) is a lethal, muscle degenerative disease causing premature death of affected children. DMD is characterized by mutations in the dystrophin gene that result in a loss of the dystrophin protein. Loss of dystrophin causes an associated reduction in proteins of the dystrophin glycoprotein complex, leading to contraction-induced sarcolemmal weakening, muscle tearing, fibrotic infiltration and rounds of degeneration and failed regeneration affecting satellite cell populations. The α7β1 integrin has been implicated in increasing myogenic capacity of satellite cells, therefore restoring muscle viability, increasing muscle force and preserving muscle function in dystrophic mouse models. In this study, we show that a Food and Drug Administration (FDA)-approved small molecule, Sunitinib, is a potent α7 integrin enhancer capable of promoting myogenic regeneration by stimulating satellite cell activation and increasing myofiber fusion. Sunitinib exerts its regenerative effects via transient inhibition of SHP-2 and subsequent activation of the STAT3 pathway. Treatment of mdx mice with Sunitinib demonstrated decreased membrane leakiness and damage owing to myofiber regeneration and enhanced support at the extracellular matrix. The decreased myofiber damage translated into a significant increase in muscle force production. This study identifies an already FDA-approved compound, Sunitinib, as a possible DMD therapeutic with the potential to treat other muscular dystrophies in which there is defective muscle repair.
(© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.)
References: Oncotarget. 2015 Feb 20;6(5):3043-54. (PMID: 25460504)
Hum Mol Genet. 2006 Mar 15;15(6):989-98. (PMID: 16476707)
Neurol Clin. 2014 Aug;32(3):671-88, viii. (PMID: 25037084)
Acta Myol. 2012 Dec;31(3):184-95. (PMID: 23620650)
Physiol Rev. 2013 Jan;93(1):23-67. (PMID: 23303905)
Cell Rep. 2016 Aug 23;16(8):2102-2115. (PMID: 27524611)
J Paediatr Child Health. 2015 Aug;51(8):759-64. (PMID: 25752877)
Nat Med. 2014 Oct;20(10):1182-6. (PMID: 25194572)
Drug Des Devel Ther. 2017 Feb 28;11:533-545. (PMID: 28280301)
J Histochem Cytochem. 2002 Dec;50(12):1579-89. (PMID: 12486080)
Skelet Muscle. 2012 Dec 05;2(1):26. (PMID: 23216833)
Am J Physiol Cell Physiol. 2013 Jan 15;304(2):C128-36. (PMID: 23114963)
Connect Tissue Res. 2015 Feb;56(1):1-8. (PMID: 25047058)
Nat Med. 2014 Oct;20(10):1174-81. (PMID: 25194569)
Stem Cell Rev Rep. 2015 Dec;11(6):866-84. (PMID: 26323256)
Brain Dev. 2016 Oct;38(9):785-91. (PMID: 27112384)
Skelet Muscle. 2015 Jul 15;5:22. (PMID: 26180627)
J Vis Exp. 2013 Jan 31;(71):e50036. (PMID: 23407283)
Am J Physiol Cell Physiol. 2011 Oct;301(4):C938-46. (PMID: 21753185)
Mol Ther. 2017 Jun 7;25(6):1395-1407. (PMID: 28391962)
Neuromuscul Disord. 2010 Jan;20(1):61-3. (PMID: 19875288)
Cancer Chemother Pharmacol. 2012 Apr;69(4):1021-7. (PMID: 22179104)
J Cell Sci. 1997 Nov;110 ( Pt 22):2873-81. (PMID: 9427295)
Neuromuscul Disord. 2006 Apr;16(4):249-55. (PMID: 16545568)
Biochim Biophys Acta. 2010 Sep;1804(9):1713-22. (PMID: 20472103)
Cytokine. 2009 Apr;46(1):137-41. (PMID: 19223199)
Neoplasia. 2009 May;11(5):426-35. (PMID: 19412427)
Am J Physiol Cell Physiol. 2002 Jul;283(1):C204-11. (PMID: 12055089)
Cell. 1988 Aug 12;54(4):447-52. (PMID: 3042151)
Oncologist. 2009 Aug;14(8):800-5. (PMID: 19648603)
J Biol Chem. 2005 Oct 28;280(43):36037-46. (PMID: 16129691)
PLoS One. 2011 Mar 09;6(3):e17392. (PMID: 21408055)
Cancer Chemother Pharmacol. 2007 Aug;60(3):357-64. (PMID: 17136543)
Exp Cell Res. 2009 Aug 1;315(13):2284-92. (PMID: 19393645)
Cell. 1987 Dec 24;51(6):919-28. (PMID: 3319190)
Cell Tissue Res. 1999 Apr;296(1):183-90. (PMID: 10199978)
Cell Prolif. 2013 Aug;46(4):365-73. (PMID: 23869758)
Curr Opin Genet Dev. 2002 Jun;12(3):349-61. (PMID: 12076680)
Mol Cell Biol. 1997 Nov;17(11):6508-16. (PMID: 9343414)
Front Cell Dev Biol. 2014 Jan 30;2:1. (PMID: 25364710)
Clin Cancer Res. 2011 Aug 1;17(15):5113-22. (PMID: 21690570)
J Biol Chem. 1996 Sep 13;271(37):22915-22. (PMID: 8798472)
Springerplus. 2016 May 13;5:619. (PMID: 27330885)
PLoS One. 2009 Jun 24;4(6):e6027. (PMID: 19554087)
Trends Mol Med. 2016 Jun;22(6):479-496. (PMID: 27161598)
Proc Natl Acad Sci U S A. 1998 Sep 15;95(19):11107-12. (PMID: 9736697)
Biomed Res Int. 2014;2014:965631. (PMID: 24877152)
J Appl Physiol (1985). 2013 Nov 1;115(9):1388-92. (PMID: 23990247)
PLoS One. 2013;8(2):e57141. (PMID: 23451164)
Hum Gene Ther. 2015 Oct;26(10):647-56. (PMID: 26076707)
Am J Pathol. 2005 Jan;166(1):253-63. (PMID: 15632017)
Hum Mol Genet. 2012 Oct 15;21(20):4378-93. (PMID: 22798625)
Nat Genet. 1998 May;19(1):94-7. (PMID: 9590299)
Mol Ther. 2013 Mar;21(3):520-5. (PMID: 23319059)
Nat Med. 2015 Dec;21(12):1455-63. (PMID: 26569381)
J Cell Biol. 2001 Mar 19;152(6):1207-18. (PMID: 11257121)
Biosci Biotechnol Biochem. 2012;76(10):1866-70. (PMID: 23047097)
J Gen Physiol. 2010 Jul;136(1):29-34. (PMID: 20584890)
Nat Rev Mol Cell Biol. 2016 May;17(5):267-79. (PMID: 26956195)
Cell Metab. 2008 Jan;7(1):33-44. (PMID: 18177723)
Methods Mol Biol. 2017;1560:179-188. (PMID: 28155153)
Biochem J. 2003 Jun 1;372(Pt 2):495-502. (PMID: 12593670)
J Cell Sci. 2006 Jun 1;119(Pt 11):2185-95. (PMID: 16684813)
J Clin Oncol. 2006 Jan 1;24(1):25-35. (PMID: 16314617)
معلومات مُعتمدة: R01 AR064338 United States AR NIAMS NIH HHS
المشرفين على المادة: 0 (Integrins)
0 (MyoD Protein)
0 (MyoD1 myogenic differentiation protein)
0 (Myogenin)
0 (STAT3 Transcription Factor)
EC 3.1.3.48 (Protein Tyrosine Phosphatase, Non-Receptor Type 6)
EC 3.1.3.48 (Ptpn6 protein, mouse)
KYD8S41U3X (integrin alpha7beta1)
V99T50803M (Sunitinib)
تواريخ الأحداث: Date Created: 20190227 Date Completed: 20200330 Latest Revision: 20200707
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC6586148
DOI: 10.1093/hmg/ddz044
PMID: 30806670
قاعدة البيانات: MEDLINE
الوصف
تدمد:1460-2083
DOI:10.1093/hmg/ddz044